Related Experiment Video
Updated: Aug 9, 2026
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Drug resistance in epilepsy: human epilepsy
S M Sisodiya1, W R Lint, B N Harding
1University Department of Clinical Neurology, Institute of Neurology, University College London, UK.
Novartis Foundation Symposium
|May 7, 2002
Summary
Drug resistance proteins like P glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) are expressed in brain tissue from epilepsy patients. This suggests their potential role in refractory epilepsy drug resistance.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- The mechanisms underlying drug resistance in human epilepsy remain unclear.
- Drug resistance in cancer shares similarities, suggesting a role for drug resistance proteins.
Purpose of the Study:
- To investigate the potential role of drug resistance proteins in refractory epilepsy.
- To examine the expression of P glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) in human brain tissue associated with epilepsy.
Main Methods:
- Immunohistochemistry was used to detect Pgp and MRP1 expression.
- Human brain tissue samples from epilepsy cases (malformation of cortical development, hippocampal sclerosis, dysembryoplastic neuroepithelial tumours) and controls were analyzed.
Main Results:
- Pgp and MRP1 were expressed in glia in various epilepsy-associated pathologies.
- Dysplastic neurons also showed MRP1 expression in a specific malformation type.
- Overexpression was often concentrated around blood vessels.
- Expression patterns suggest some pathologies may have constitutive Pgp and MRP1 expression.
Conclusions:
- The findings suggest that drug resistance proteins, Pgp and MRP1, may contribute to the development of drug resistance in refractory epilepsy.
- Further research is warranted to elucidate the precise role of these proteins in epilepsy treatment.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...